Mitochondrial Paths to Sarcopenia – A Refined Short Review

Abstract: The current revision aims to report on the geriatric syndrome, well known as sarcopenia, specifically the communication between sarcopenia and mitochondrial pathways. It is predicted that pervasiveness of sarcopenia in community-dwelling elderly people is around 25%, and there is a 5% loss of muscle mass per decade of life from the fourth decade onwards, possibly progressing after the age of 65 years. Muscular mass usually supplies up to ∼50% of total body weight in grown-ups but drops to 25% with aging at 75-80 years old. In the past, several molecular mediators contributing to sarcopenic muscle loss involves ubiquitin proteasomes, inflammatory molecules, and autophagy(definition). Currently, the central roles of mitochondria in the management of sarcopenia are underpinned. However, the collection of scientific evidence suggests that mitochondria have built both direct and indirect physiological implications in controlling muscle physiology and muscle mass in both healthy and diseased conditions, specifically in sarcopenia, the role of mitochondrial pathways epitomize an assuring area of exploration. It is advisable to have an overview of latest discoveries highlighting the mitochondrial function in sarcopenia to generate innovative remedies that can aid to enhance, manage or slow down age-related muscle loss. In the current review, we discuss relevant scientific studies delineating mitochondrial roles and pharmacological therapeutics of sarcopenia.